Long-term treatment with bevacizumab is tolerable for patients with solid tumors, according to research published in The Oncologist.

Researchers conducted a long-term extension study to evaluate the safety of bevacizumab in patients with solid tumors. The study included 95 patients who received bevacizumab alone or in combination on 1 of 17 clinical trials.

The patients had ovarian or peritoneal carcinoma (41 patients), non-small cell lung cancer (16 patients), glioblastoma (14 patients), breast cancer (11 patients), colorectal cancer (17 patients), and renal cell carcinoma (6 patients).


Continue Reading

Most patients were women (70.5%), the median age at baseline was 56 years (range, 23-81 years), and the median observation time was 20.7 months.

The median duration of bevacizumab treatment was 57.5 months overall and 15.6 months during this long-term extension study. Three patients received bevacizumab for more than 10 years.

Common reasons for treatment discontinuation included disease progression (31.6%) and adverse events (AEs; 26.3%).

Treatment-related AEs of any grade occurred in 56.8% of patients. Grade 3 or higher treatment-related AEs occurred in 22.1%. The most common grade 3 or higher AEs were proteinuria (7.4%), hypertension (5.3%), and blood pressure increase (2.1%).

Serious AEs were observed in 17.9% of patients. The most common serious AEs were infections and infestations (4.2%); injury, poisoning, and procedural complications (3.2%); vascular disorders (3.2%); cardiac disorders (2.1%); and nervous system disorders (2.1%).

There were 4 deaths during the extension study, none of which were related to bevacizumab. Three patients died from disease progression, and 1 died from an AE unrelated to bevacizumab.

“The overall safety outcomes observed support the tolerability of long-term bevacizumab treatment in patients with various solid tumors, with clinical benefit achieved over an extended period,” the researchers wrote.

Disclosures: All clinical trials included in this analysis were sponsored by Roche-Genentech. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures. 

Reference

Oza AM, Dubois F, Hegg R, et al. A long-term extension study of bevacizumab in patients with solid tumors. Oncologist. Published online September 9, 2021. doi:10.1002/onco.13971